An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome

Takayuki Matsumura1*†, Ayae Nishiyama1†, Michio Aiko1, Akira Aina1, Tadayoshi Ikebe3, Joe Chiba2, Manabu Ato4 and Yoshimasa Takahashi1*

Abstract

Objective: Streptococcus pyogenes (Group A Streptococcus; GAS) causes a variety of infections that include life-threatening, severe invasive GAS infections, such as streptococcal toxic shock syndrome (STSS), with > 30% mortality rate, despite effective antibiotics and treatment options. STSS clinical isolates highly express streptolysin O (SLO), a member of a large family of pore-forming toxins called cholesterol-dependent cytolysins (CDCs). SLO is an important toxic factor for GAS and may be an effective therapeutic target for the treatment of STSS. Our aim was to identify a monoclonal antibody (mAb) that reacts with SLO and has therapeutic potential for STSS treatment.

Results: We focused on mAbs that had originally been established as neutralizing reagents to perfringolysin O (PFO), another member of the CDC family, as some cross-reactivity with SLO had been reported. Here, we confirmed cross-reactivity of an anti-PFO mAb named HS1 with SLO. In vitro analysis revealed that HS1 mAb sufficiently prevented human neutrophils from being killed by STSS clinical isolates. Furthermore, prophylactic and therapeutic injection of HS1 mAb into C57BL/6 mice significantly improved the survival rate following lethal infection with an STSS clinical isolate. These results highlight the therapeutic potential of HS1 mAb for STSS treatment.

Keywords: Streptococcal toxic shock syndrome, Cholesterol-dependent cytolysins, Streptolysin O, Perfringolysin O, Neutralizing monoclonal antibody

Introduction

Streptococcus pyogenes, also known as group A Streptococcus (GAS), is one of the most common human pathogens, and causes a wide spectrum of diseases ranging from pharyngitis and skin lesions to streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis. The first two are generally self-limiting, while the latter two are severe and life-threatening, with mortality rates of 30–70% even with immediate antibiotic therapy and intensive care [1–4]. Therefore, GAS is sometimes referred to as “killer microbes” or “flesh-eating bacteria” [5]. The prevalence of severe GAS disease is at least 18.1 million cases globally each year [6], including annual estimates of 8000–24,000 invasive cases; the numbers have been increasing since 2013 in the United States [7]. In addition, in Japan, there are 90–1000 cases of severe invasive streptococcal infections annually, and the number of cases has been similarly increasing since 2014 [8].

Severe invasive GAS clinical isolates often express virulence factors more abundantly than non-invasive
For example, STSS clinical isolates highly express streptolysin O (SLO), which belongs to a large family of pore-forming toxins called the cholesterol-dependent cytolysins (CDCs) [9–13]. SLO has been shown to be a key virulence factor of GAS by preventing internalization of the bacteria into lysosomes where they can be destroyed [14], and has cytopathic effects on neutrophils, macrophages, and dendritic cells [15–19]. As a result, STSS causes severe neutropenia, which results in poor prognosis for the patients and the mouse model [20, 21]. The global increase in invasive GAS infections in the 1980s was associated with the emergence of an M1T1 clone that harbors a 36-kb pathogenicity island that codes for increased expression of SLO and its co-toxin NAD⁺-glycohydrolase [22–25]. Taken together, SLO is a potential therapeutic target for the treatment of STSS.

Several hybridomas that produce monoclonal antibodies (mAbs) specific for Clostridium perfringens-derived perfringolysin O (PFO) in the CDC family [26] have been cryopreserved in liquid nitrogen since 1984. Among the original mAbs (4D8, 2C5, and 3H10), 3H10 mAb was found to neutralize PFO and SLO, and inhibited toxin-induced hemolysis of sheep red blood cells and cardiotoxicity in cultured mouse heart cells [26]. The aim of the present study was to re-clone the existing hybridomas and test the specificity of the mAbs against SLO, in an attempt to identify a novel treatment strategy for STSS.

**Main text**

**Methods**

**Blinding at any stage of the study**

The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.

**Re-cloning of hybridomas**

Hybridomas that produce mAbs (mouse IgG1) reactive with PFO were recovered from liquid nitrogen. 3H10 and 2C5 hybridomas were re-cloned by the limiting dilution method at 0.3 cell/well in a 96-well plate, resulting in 7 and 11 colonies, respectively. 4D8 hybridoma was re-cloned at 1 cell/well in a 96-well plate, resulting in 5 colonies. The re-cloned hybridomas 3H10, 4D8, and 2C5 that showed the most potent binding activities against PFO were renamed HS1, HS2, and HS3, respectively.

**Enzyme-linked immunosorbent assay (ELISA)**

First, 96-well plates were coated with 50 μL (1 μg/ml) of PFO (MyBioSource, San Diego, CA) or SLO (Bio Academia, Osaka, Japan). The plates were washed four times with 0.1% Tween20 in sterile PBS (PBS-T), and then blocked with 1% BSA in PBS-T for 2 h at room temperature; the diluted HS1, HS2, and HS3 were incubated for 2 h at room temperature. After the samples were washed with PBS-T, they were incubated with anti-mouse IgG conjugated to horseradish peroxidase (Southern Biotech, Birmingham, AL) for 2 h at room temperature. After washing the samples with PBS-T, 0.5 mg/ml o-Phenylenediamine dihydrochloride (Sigma-Aldrich) in 0.05 M citrate–phosphate buffer (pH 5.0) was used for detection. Absorbance was read at a wavelength of 490 nm with an iMark Microplate Reader (Bio-Rad, Hercules, CA).

**Immunoblotting**

Equal amount (1 μg/ml) of PFO (MyBioSource, San Diego, CA) or SLO (Bio Academia, Osaka, Japan) was suspended in SDS sample buffer (Bio-Rad), and boiled for 5 min. The proteins (10 ng/10 μl) were separated by SDS-PAGE, and then transferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA). Membranes were then probed with HS1, HS2, and HS3 mAbs at a concentration of 1 μg/ml as the primary antibody. Subsequently, membranes were labeled with anti-mouse IgG conjugated to horseradish peroxidase (GE Healthcare, Buckinghamshire, UK), and visualized using the ECL Western Blotting Detection System (GE Healthcare).

**Bacterial strains**

The invasive strains NIH34 (emm3 genotype) and NIH230 (emm49 genotype) were isolated by the Working Group for Beta-hemolytic Streptococci in Japan [16] from a patient with STSS, diagnosed as per the criteria proposed by the Working Group on Severe Streptococcal Infections [27]. The culture and preparation of bacteria were performed as previously described [28].

**Human neutrophil killing assay**

Human neutrophils were isolated from the venous blood of two healthy volunteers, in accordance with a protocol approved by the Institutional Review Board for Human Subjects, National Institute of Infectious Diseases, Japan (Permit number: 756). This study complies with the guidelines of the Declaration of Helsinki. A modified chemotaxis assay was performed as previously described [15, 16]. Briefly, 3 × 10⁵ neutrophils in Roswell Park Memorial Institute medium containing 25 mM HEPEs and 1% FBS were cultured on Transwell inserts (3 μm pore size, Coaster, Corning, NY) in 24-well plates containing 600 μl medium, or 100 nM interleukin (IL)-8 solution (Peprotec, London, UK); these were incubated with or without 3 × 10⁸ bacteria in the absence or presence of HS1, HS2, HS3 mAbs, and control mouse IgG (Rockland, Gilbertsville, PA) for 60 min at 37 °C prior to the assay. After 60 min incubation, cells in the lower wells were collected and
10^4 10 μm microsphere beads (Polysciences Inc., Warrington, MA) were added. Cells were stained with propidium iodine (Sigma-Aldrich) for flow cytometry to quantitate viable neutrophils, and were analyzed using a FACSCalibur (Becton, Dickinson and Company).

**GAS infection in a mouse model**

All animal protocols were approved by the Animal Experiments Committee at the National Institute of Infectious Diseases (Permit numbers: 116044, 118014), and were compliant with the Guide for Animal Experiments Performed at the National Institute of Infectious Diseases, Japan. Six-week old C57BL/6 male mice, 20–25 g, were purchased from Japan SLC (Shizuoka, Japan), and maintained in specific pathogen-free conditions. Mice were kept in collective cages (5–6 mice/cage) under a 12-h light/dark cycle and received water and feed ad libitum. GAS isolate (4.0 × 10^7 colony-forming units in 0.5 ml PBS) was inoculated intraperitoneally into 6-week old C57BL/6 male mice (5 or 6 mice per group). 1 h before or after infection, mice were administered an intraperitoneal injection of HS1, HS2, HS3 mAbs, and control mouse IgG (Rockland) (1 mg per mouse). Mouse survival was monitored daily for the indicated time period. At the end of the experiment and the humane endpoint, mice were euthanized by cervical dislocation under anesthesia. The humane endpoint was applied when abnormal appearance over a prolonged period with no visible indications of recovery was observed.

**Statistical analysis**

Data are expressed as mean ± standard deviation (SD). Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA). Statistical significance was determined by the log-rank test. A value of p < 0.05 was considered statistically significant. *p < 0.05. The number of animals used in each experiment was determined on the basis of previously obtained results with the experimental model system [21, 28]. Figure legends indicate the number of independent experiments and biological replicates (n) used for statistical analysis.

**Results**

**Cross-reactivity of anti-PLO mAbs with SLO**

Hybridomas that produce neutralizing mAbs 3H10, 4D8, and 2C5 against PFO [26] were re-cloned and renamed HS1, HS2, and HS3, respectively. We examined cross-reactivity of these mAbs by ELISA (Fig. 1a) and immunoblotting (Fig. 1b and Additional file 1: Fig. S1). HS1 mAb, but not HS2 and HS3 mAbs, was reactive with SLO. These results suggest that HS1 mAb may recognize a certain common epitope or similar structure on both PFO and SLO.

**The neutralizing mAb HS1 treatment improves the survival rate of neutrophils in the presence of STSS clinical isolates**

We next investigated the neutralizing capacity of HS1, HS2, and HS3 mAbs for the cytotoxic activity of SLO against human neutrophil survival in the presence of an STSS clinical isolate. We have previously established a

![Fig. 1](https://example.com/fig1.png)
sensitive in vitro assay for GAS virulence based on SLO activity, by measure of neutrophil viability using a modified chemotaxis assay [15, 16]; human neutrophils that migrate into lower wells in response to IL-8 are killed by the SLO-producing STSS clinical isolates in a contact-dependent manner [15, 16]. Figure 2 shows that killing of human neutrophils by the STSS clinical isolates was inhibited by HS1 mAb. Control IgG, HS2, and HS3 mAbs did not inhibit neutrophil killing by the STSS clinical isolate (Fig. 2a and b). These results suggested that HS1 mAb was acting as a neutralizing mAb against SLO.

Pre- and post-treatment with HS1 mAb improves survival of mice infected with an STSS clinical isolate
To verify the effect of the neutralizing mAb HS1 on infection in vivo, a 7-day survival rate was undertaken, using a mouse model intraperitoneally infected with an STSS clinical isolate. Pre-treatment with HS1 mAb, but not control IgG, HS2, and HS3 mAbs, significantly improved the survival rate of mice infected with the STSS clinical isolate (Fig. 3a). Furthermore, post-treatment with HS1 mAb also, but not control IgG, HS2, and HS3 mAbs, improved the survival rate of mice infected with the STSS clinical isolate (Fig. 3b).

Discussion
Recently, high mortality in STSS patients has not been significantly reduced despite adequate antibiotic treatment in high-income countries, and the efficacy of combined antibiotic therapy and adjunctive intravenous immunoglobulin (IVIG) therapy in STSS has been evaluated [29]. A high dosage (0.5–1.0 g/kg) of IVIG is required for IVIG therapy, which is expensive and difficult to achieve. Therefore, the development of targeted therapy for STSS virulence factors is required. We have previously reported that SLO is one of the major virulence factors in STSS [15, 16]. Here, we demonstrated that antibody therapy against SLO may be a new adjunctive treatment for STSS.

In this study, the ability of an STSS clinical isolate to kill neutrophils was inhibited by the addition of HS1 mAb, but not HS2 and HS3 mAbs. Furthermore, in the mouse model, pre- and post-treatment with HS1 mAb, but not HS2 and HS3 mAbs, significantly increased the survival rate of mice infected with an STSS clinical isolate. These results suggest that HS1 mAb, which prevents neutrophil death in GAS infection, may be used as an adjunctive protective antibody for STSS.

SLO belongs to a large family of pore-forming toxins called CDCs [9–13]. CDCs are secreted by gram-positive bacteria, including Bacillus, Listeria, Lysinibacillus, Paenibacillus, Brevibacillus, Streptococcus, Clostridium, Gardnerella, Arcanobacterium, and Lactobacillus [30]. Notably, it has been reported that PFO neutralizing mAb 3H10, an original clone of HS1 mAb, has cross-reactivity not only with SLO but also with Clostridium bifermentans-derived bifermentolysin and Clostridium sordellii-derived sordelliolysin [26, 31]. If HS1 mAb binds to other CDCs and can neutralize them as well as SLO, PFO, bifermentolysin, and sordelliolysin, HS1 mAb may become an effective adjunctive therapeutic antibody for many gram-positive bacterial infections.

**Fig. 2** Effects of HS1 mAb treatment on STSS clinical isolate-infected human neutrophils. The results show the proportion of live neutrophils that migrated into lower wells in response to IL-8 alone (no bacteria) or IL-8 in the presence of the STSS clinical isolates (a) NIH34 (emm3) and (b) NIH230 (emm49) (3 x 10⁶ colony-forming units/well) treated with or without 1 μg/ml or 10 μg/ml HS1, HS2, HS3 mAbs, and control mouse IgG. Data are expressed as mean ± SD (n = 3). Data are representative of two independent experiments.
Limitations
We did not identify the specific conformational epitope of SLO and PFO recognized by HS1 mAb. In vivo protection assays were performed using only one strain, single dose, and intraperitoneal route of mAb administration.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13104-020-05264-2.

Fig. 3  Effect of HS1 mAb administration on STSS clinical isolate-infected mice. C57BL/6 mice (male, 6-week-old) were intraperitoneally inoculated with NIH34 (4 × 10⁷ colony-forming units per mouse). HS1, HS2, HS3 mAbs, and control mouse IgG (1 mg per mouse) were administrated 1 h a before (n = 11 mice per group) or b after infection (n = 12 mice per group). Mouse survival was monitored for the indicated time period. The combined data from two independent experiments (n = 5 or 6 mice per group) are shown. *p < 0.05 by log-rank test versus control mouse IgG-treated group

Abbreviations
CDC: Cholesterol-dependent cytolysin; GAS: Group A Streptococcus; mAb: Monoclonal antibody; PFO: Perfringolysin O; SLO: Streptolysin O; STSS: Streptococcal toxic shock syndrome.

Acknowledgements
We thank Dr. Hiroko Sato for kindly providing hybridomas (clone 3H10, 4D8, and 2C5). We also thank Eriko Izumiyama, Akira Dosaka, Aoi Iguchi, Ikuko Togashi, and Ryoko Itami for technical support.

Authors’ contributions
TM conceived the study design, obtained funding and ethics approvals, performed the experiments, interpreted the data, and wrote the draft manuscript. AN performed the experiments, interpreted the data, and wrote the draft manuscript. MA performed the experiments. AA and TI provided advice on the study design, interpreted the data, and revised the draft manuscript. JC conceived the study design, interpreted the data, and revised the draft manuscript. YT conceived the study design, interpreted the data, wrote the draft manuscript, and supervised the study. All authors read and approved the final manuscript.

Funding
This work was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP20fk0108130 (TM), Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP20k08833 (TM), and the Takeda Science Foundation (TM).

Availability of data and materials
Complete sequence data that support the findings of this study have been deposited in the DNA Data Bank of Japan (DDBJ), the EMBL Nucleotide Sequence Database, and GenBank under the following accession numbers (LC545573, LC545574, LC545575, LC545576, LC545577, LC545578). The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study protocol was approved by the National Institute of Infectious Diseases Ethic Review Board for Human Subjects (Permit number: 756) and the animal experiments were approved by the National Institute of Infectious Diseases Animal Experiments Committee (Permit numbers: 116044, 118014). All participants provided written informed consent in accordance with the Declaration of Helsinki. All animal experiments were performed according to the Guide for Animal Experiments Performed at National Institute of Infectious Diseases, Japan.

Consent for publication
Not applicable.

Competing interests
TM, J.C., M.Ato, and Y.T. have filed a patent application for antibodies HS1, HS2, and HS3 with the National Institute of Infectious Diseases.

Author details
1 Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. 2 Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. 3 Department of Bacteriology I, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. 4 Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, 4-2-1 Aobacho, Higashimurayamashi, Tokyo 189-0002, Japan.

Received: 15 May 2020  Accepted: 1 September 2020
Published online: 05 September 2020

References
1. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9:281–90.
2. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13:470–511.
3. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med. 1996;335:547–54.
4. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334:240–5.
5. Stevens DL. The toxins of group A Streptococcus, the flesh eating bacteria. Immunol Invest. 1997;26:129–50.
6. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–94.
7. Centers for Disease Control and Prevention (CDC), Surveillance Reports (from 1997 to 2017). https://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed 29 Jan 2020.
8. National Institute of Infectious Diseases, Infectious Diseases Weekly Report Japan (from 2006 to 2019). https://www.niid.go.jp/niid/ja/idwr.html. Accessed 29 Jan 2020.
9. Tweten RK, Parker MW, Johnson AE. The cholesterol-dependent cytolsins. Curr Top Microbiol Immunol. 2001;257:15–33.
10. Parker MW, Feil SC. Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol. 2005;88:91–142.
11. Tweten RK. Cholesterol-dependent cytolsins, a family of versatile pore-forming toxins. Infect Immun. 2005;73:6199–209.
12. Hotze EM, Tweten RK. Membrane assembly of the cholesterol-dependent cytolsin pore complex. Biochim Biophys Acta. 2012;1818:1028–38.
13. Rebold CF, Whisstock JC, Dunstone MA. Giant MACPF/CDC pore forming toxins: a class of their own. Biochim Biophys Acta. 2016;1858:475–86.
14. Hakansson A, Bentley CC, Shakhnovic EA, Wessels MR. Cytolysin-dependent evasion of lysoosomal killing. Proc Natl Acad Sci USA. 2005;102:5192–7.
15. Ato M, Ikebe T, Kawabata H, Takemori T, Watanabe H. Incompetence of neutrophils to invasive group A Streptococcus is attributed to induction of plural virulence factors by dysfunction of a regulator. PLoS ONE. 2008;3:e3455.
16. Ikebe T, Ato M, Matsumura T, Hasegawa H, Sata T, Kobayashi K, et al. Highly frequent mutations in negative regulators of multiple virulence genes in group A streptococcal toxic shock syndrome isolates. PLoS Pathog. 2010;6:e1000832.
17. Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, et al. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J Biol Chem. 2009;284:862–71.
18. Goldmann O, Sastala I, Wos-Oxley M, Rohde M, Medina E. Streptococcus pyogenes induces ancosis in macrophages through the activation of an inflammatory programmed cell death pathway: Cell Microbiol. 2009;11:138–55.
19. Cortes G, Wessels MR. Inhibition of dendritic cell maturation by group A Streptococcus. J Infect Dis. 2009;200:1152–61.
20. Eriksson BK, Andersson J, Holm SE, Norgren M. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis. 1998;27:1428–36.
21. Matsumura T, Ato M, Ikebe T, Ohnishi M, Watanabe H, Kobayashi K. Interferon-γ-producing immature myeloid cells confer protection against severe invasive group A Streptococcus infections. Nat Commun. 2012;3:678.
22. Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW, et al. Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A. 2014;111:E1768–76.
23. O’Seaghdha M, Wessels MR. Streptolysin O and its co-toxin NAD-glycohydrolase protect group A Streptococcus from Xenophagic killing. PLoS Pathog. 2013;9:e1003394.
24. Bastiat-Sempe B, Love JF, Lomayevesa N, Wessels MR. Streptolysin O and NAD-glycohydrolase prevent phagolysosome acidification and promote group A Streptococcus survival in macrophages. MBio. 2014;5:e01690.
25. Velarde JJ, Seaghdha M, Baddock B, Bastiat-Sempe B, Wessels MR. Binding of NAD(+)glycohydrolase to streptolysin O stabilizes both toxins and promotes virulence of group A Streptococcus. Bio Res. 2017;8(5):e01382.
26. Sato H, Ito A, Chiba J. Cross-reactivity of monoclonal antibodies against Clostridium perfringens B toxin with streptolysin O. Curr Microbiol. 1984;10:243–8.
27. Breiman RF, Davis JP, Facklam RR, Gray BM, Hoge CW, Kaplan EL, et al. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993;269:390–1.
28. Matsumura T, Ikebe T, Arikawa K, Hosokawa M, Akio M, Iguchi A, et al. Sequential sensing by TLR2 and Miclone directs immature myeloid cells to protect against invasive group A streptococcal infection in mice. Cell Rep. 2019;27:561–71.
29. Linner A, Darenberg J, Spolin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59:851–7.
30. Johnson BB, Heuck AP. Perfringolysin O structure and mechanism of pore formation as a paradigm for cholesterol-dependent cytolsins. Subcell Biochem. 2014;80:63–81.
31. Sato H. Monoclonal antibodies against Clostridium perfringens B toxin (Perfringolysin O). In: Macario AIL, de Macario EC, editors. Monoclonal antibodies against bacteria, vol. III. Amsterdam: Elsevier; 1986. p. 203–28.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.